STAT+: Democrats press White House on who got special access to Eli Lilly’s new obesity drug
Why this matters: health reporting relevant to everyday decisions and well-being.
WASHINGTON — Democratic lawmakers have questions about the 79-year-old patient who received special access in April to retatrutide, Eli Lilly’s experimental obesity drug, and are pressing the Trump administration on if the person is the president or another prominent figure.&#x A0; STAT reported on Tuesday that Eli Lilly and the Food and Drug Administration offered the drug to the patient, who has refractory obesity, obstructive sleep apnea, and pulmonary hypertension, via the FDA’s “compassionate use” program. This pathway gives patients with serious and immediately life-threatening medical issues access to experimental treatments.Continue to STAT+ to read the full story…